$27.83
2.92% day before yesterday
Nasdaq, Jun 06, 10:08 pm CET
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Viking Therapeutics, Inc. Stock price

$27.83
+0.82 3.04% 1M
-22.97 45.22% 6M
-12.41 30.84% YTD
-27.18 49.41% 1Y
+20.25 267.15% 5Y
+19.81 247.01% 10Y
+18.87 210.60% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.79 2.92%
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Key metrics

Market capitalization $3.13b
Enterprise Value $2.27b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.69
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-172.32m
Free Cash Flow (TTM) Free Cash Flow $-133.99m
Cash position $851.86m
EPS (TTM) EPS $-1.15
P/E forward negative
P/S forward 2,125.39
EV/Sales forward 1,546.12
Short interest 27.29%
Show more

Is Viking Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Viking Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Viking Therapeutics, Inc. forecast:

17x Buy
89%
2x Hold
11%

Analyst Opinions

19 Analysts have issued a Viking Therapeutics, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Viking Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
43% 43%
-
- Research and Development Expense 119 119
55% 55%
-
-172 -172
-
-
- Depreciation and Amortization 0.46 0.46
-
-
EBIT (Operating Income) EBIT -172 -172
51% 51%
-
Net Profit -128 -128
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viking Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viking Therapeutics, Inc. Stock News

Positive
Seeking Alpha
5 days ago
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in multiple metabolic diseases, making it an attractive acquisition target. VKTX's VK2735 offers strong weight loss efficacy and dual formulation flexibility, but faces tough competition and lacks cle...
Positive
The Motley Fool
6 days ago
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (LLY 2.28%) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years.
Positive
The Motley Fool
6 days ago
Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date amid President Trump's global trade reset and persistent inflation concerns, the easy gains of prior years have evaporated.
More Viking Therapeutics, Inc. News

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Brian Lian
Employees 46
Founded 2012
Website vikingtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today